The relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6 in benign and malignant human lymphoid tissues  by Baron, Beverly W. et al.
Biochemistry and Biophysics Reports 6 (2016) 1–8Contents lists available at ScienceDirectBiochemistry and Biophysics Reportshttp://d
2405-58
n Corr
E-m
RBARON
jbaron@journal homepage: www.elsevier.com/locate/bbrepThe relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6
in benign and malignant human lymphoid tissues
Beverly W. Baron a,n, Rebecca M. Baron b, Joseph M. Baron c
a Department of Pathology, The University of Chicago, CCD, Room 2600, MC8049, 5720 S. Drexel Avenue, Chicago, IL 60637, USA
b Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
c Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USAa r t i c l e i n f o
Article history:
Received 19 October 2015
Received in revised form
31 January 2016
Accepted 9 February 2016
Available online 10 February 2016
Keywords:
RUVBL1
Pontin
TIP49
NMP238
BCL6 target
Lymphomagenesisx.doi.org/10.1016/j.bbrep.2016.02.006
08/& 2016 The Authors. Published by Elsevier
esponding author.
ail addresses: Beverly.Baron@uchospitals.edu (
@PARTNERS.ORG (R.M. Baron),
medicine.bsd.uchicago.edu (J.M. Baron).a b s t r a c t
The human BCL6 gene, which is involved in the pathogenesis of certain human lymphomas, encodes a
transcriptional repressor that is needed for germinal center B cell development and T follicular helper
cell differentiation. Our goal was to identify BCL6 target genes using a cell system in which BCL6 re-
pressive effects are inhibited followed by subtractive hybridization, and we detected the RUVBL1 (Pontin,
TIP49) gene as a potential target of BCL6 repression. Here we show that the BCL6 protein signiﬁcantly
represses RUVBL1 transcription (6.8-fold). Knockdown of endogenous BCL6 in a human B cell lymphoma
line leads to signiﬁcant upregulation of RUVBL1, and there is an inverse expression pattern between the
BCL6 and RUVBL1 proteins in certain human lymphomas. RUVBL1 is part of the AAAþ superfamily and
participates in multiple processes, including gene transcription regulation, chromatin remodeling, and
DNA repair, which, if dysregulated, may promote lymphoma development. A further understanding of
the relationship between RUVBL1 and BCL6 should improve our understanding of the pathogenesis of
human lymphomas.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The BCL6 gene on chromosome 3, band q27 accompanies the
development of certain human lymphomas and encodes a nuclear
BTB/POZ zinc ﬁnger protein – a transcriptional repressor that is
important in the formation of germinal center B cells and T folli-
cular helper cells [1–4]. BCL6 regulates gene expression via inter-
actions with corepressors that recruit histone deacetylases and
induce epigenetic remodeling and heterochromatin formation
[5,6]. To identify BCL6 target genes, we developed a dominant-
negative cell system in which BCL6 repressive effects are inhibited,
permitting the detection of genes that are ordinarily repressed. We
used subtractive hybridization to detect up-regulated messages [7]
and describe here the identiﬁcation of the RUVBL1 gene (also
called Pontin 52, Pontin, TIP49, NMP238) as a potential novel target
of BCL6 repression.
The RUVBL1 protein, expressed virtually ubiquitously, is evo-
lutionarily conserved and localizes to the cell nucleus and the
cytoplasm [8]. It is an ATPase that is part of the AAAþ(ATPases
associated with diverse cellular activities) superfamily, whichB.V. This is an open access article u
B.W. Baron),encompasses a large group of ring-shaped complexes involved in
diverse cellular processes [9], including gene transcription reg-
ulation (although RUVBL1 is not a transcription factor), chromatin
remodeling, sensing of DNA damage and repair, and the assembly
of protein and ribonucleoprotein complexes [10], any of which, if
perturbed, could potentially lead to lymphoma development.
RUVBL1 is overexpressed in many cancers [11] and its role in
carcinogenesis is under investigation. For example, in a hepato-
cyte-conditional RUVBL1þ / mouse model and Diethylni-
trosamine cancer induction protocol, tumor size was signiﬁcantly
larger in RUVBL1þ / (as compared with RUVBL1þ /þ) mice after
9 and 12 months of cancer progression, indicating the potential
risks of prolonged RUVBL1 inhibition [10].2. Materials and methods
2.1. Identiﬁcation of BCL6 repression targets by subtractive hy-
bridization and validation by Northern blotting
As described [7], we converted the BCL6 zinc ﬁngers (BCL6ZF),
which lack repressive effects but bind DNA, into a transcriptional
activator and used this construct to compete with wild-type BCL6
in BJAB cells (an Epstein-Barr virus-negative Burkitt lymphoma
cell line expressing high levels of BCL6) [12]. To convert thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Northern blotting conﬁrms differential expression of RUVBL1. (A) Representative
autoradiograph of a Northern blot made from total RNA of BJAB cells (human B cell
lymphoma line) transiently transfected with an expression construct (S, study) con-
taining the BCL6 ﬁngers or the vector (control, C) in which the S construct was cloned.
Top: Hybridization with a cDNA fragment of RUVBL1 obtained from subtractive hy-
bridization shows its 1.8 kb transcript. Bottom: The blot was stripped and hybridized
with a human β-actin probe. (B) Densitometry data showing differential expression of
RUVBL1 normalized to β-actin. For eight Northern blots, differential expression of
RUVBL1 (S lane) as compared with the control (C) is signiﬁcant by unpaired t test;
mean7SEM, 2.59370.497 (range 1.18–5.72)-fold (po0.006). The data were normal-
ized with results for the control designated as 1.
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2181 of the BCL6 cDNA, which comprise the ZF domain but not the
upstream repressor domains, to the VP16 activating domain of
herpes simplex virus that had been hemagglutinin-tagged and
subcloned in pcDNA3 (gift of Dr. J. Leiden, then at Abbott Labora-
tories, North Chicago, IL). The cells were transiently co-transfected
with the construct or the vector in which it was cloned by elec-
troporation along with p-Hook-1 (Invitrogen), a vector that directs
synthesis of a single-chain antibody, sFv, which is expressed on the
surface of transfected cells. Transfected cells were separated from
the total cell population with magnetic beads (Invitrogen) coated
with the hapten (phOx) toward which the sFv is speciﬁcally di-
rected. Subtractive hybridization was performed; inserts of cDNA
clones obtained following PCR were sequenced.
Potential BCL6 targets were 32P-labeled and hybridized to eight
Northern blots which were prepared from the total RNA of BJAB
cells that had been transiently cotransfected with the study con-
struct (BCL6ZF) or the control construct (vector) and pHook-1 and
selected on magnetic beads as described above. The blots were
washed under stringent conditions and autoradiographed, then
stripped and rehybridized with a 32P-labeled human β-actin con-
trol probe (Clontech Laboratories, Inc., Mountain View, CA), wa-
shed under stringent conditions, and reautoradiographed. Scan-
ning densitometry was used to normalize relative band intensity
to β-actin. Differential expression was compared by an unpaired t
test.
2.2. Construction of RUVBL1 promoter reporter plasmids
We identiﬁed the promoter sequences of the RUVBL1 gene
(Accession NM_003707), and then we compared the sequences
within this regionwith the preferential binding site for BCL6 ([A/T]
TC[C/T][A/T][A/C]GA) [13]. We found an exact match to 7 of these
8 bases in the RUVBL1 promoter region. To clone the sequences
surrounding this site, 0.705 kb of human genomic DNA from the
RUVBL1 promoter region was ampliﬁed by PCR (forward primer,
5′-CGGTGTGAGACTGTGGAACTAC-3′; reverse primer, 5′-
CCATCCTCCACCGAGAGATAA-3′). The PCR product was a single
band of the correct size on a 0.9% agarose gel; 1 μl of the PCR
product was blunted and ligated to 50 ng of the pJET 1.2/Blunt
Cloning Vector (Thermo Scientiﬁc, Waltham, MA) per the manu-
facturer's instructions. The appropriate insert was isolated from
this vector with BglII restriction enzyme digests and ligated to the
BglII site of the pGL3 basic luciferase reporter vector (Promega,
Madison, WI) (pGL3RUVBL1). Multiple restriction enzyme digests
conﬁrmed the correct size and proper orientation of the insert in
the vector.
2.3. Transient transfections/functional analysis
We used 293 T (human embryonic kidney) cells which are
readily transfectable and have minimal expression of endogenous
BCL6 [14] as well as RUVBL1 [www.abnova.com, Western blotting
with RUVBL1 monoclonal antibody, H00008607- M01]. They were
grown under standard conditions [15], plated in a six-well dish,
transfected at 50–60% conﬂuence by ViaFect™ Transfection Re-
agent (Promega) per the manufacturer's instructions, and har-
vested at 50 h. The constructs transfected included the BCL6
consensus binding site in the promoter region of RUVBL1
(pGL3RUVBL1 described above, 0.6 mg) and full-length BCL6 cDNA
subcloned in the pCGN expression vector (1.25 mg) or an equiva-
lent amount of a truncated BCL6 expression construct (control)
subcloned in pCGN. We used this construct in previous experi-
ments as a control [16] because it lacks the BCL6 zinc ﬁnger DNA-
binding region and therefore cannot bind DNA. A CMV-driven β-
galactosidase construct was cotransfected. Luciferase levels werenormalized for transfection efﬁciency by using the values of β-
galactosidase assays as described [16]. Relative luciferase activity
was deﬁned as the luciferase levels obtained with the BCL6 con-
struct divided by the luciferase levels obtained with the control.
An unpaired t test was used to determine whether the mean re-
lative luciferase activity of the RUVBL1 consensus binding site
from three independent experiments (triplicate wells in each) was
signiﬁcantly different from 1 in cells transfected with BCL6 vs.
those transfected with the control.
2.4. BCL6 siRNA transfections
We used electroporation to transfect BJAB cells with human
BCL6 siGENOME SMARTpool reagent or CONTROL nontargeting
siRNA 1 (Dharmacon, LaFayette, CO) as previously reported [16].
Whole cell extracts prepared from the transfected cells were
boiled and sheared in a reducing buffer (10% glycerol, 2 g% SDS, 1%
1 m Tris–HCl [pH 6.8], 5% 2-mercaptoethanol, and 0.005 gm%
bromophenol blue) and used to prepare nine Western blots as
described [16]. The antibodies employed were rabbit polyclonal
antibodies to BCL6 (sc-858 or sc-368, Santa Cruz Biotechnology,
Fig. 2. The BCL6 protein represses transcription from the RUVBL1 promoter
(transfection assays). Relative luciferase levels in 293 T cells show that RUVBL1
promoter activity is signiﬁcantly repressed (6.8-fold, po0.0001) by the full-length
BCL6 protein (mean7SEM¼0.14670.059) as compared with a truncated control
that lacks the BCL6 zinc ﬁngers and thus cannot bind DNA. The data were nor-
malized with results for the control set at 1.
Fig. 3. Knockdown of BCL6 protein levels by siRNA increases RUVBL1 protein ex-
pression. (A) Representative Western blot depicting BCL6 (95 kDa), RUVBL1
(50 kDa), and β-actin protein expression in BJAB cells 45 h after transfection with
siRNA duplexes targeting BCL6 [C, control siRNA; S, study (BCL6) siRNA]. All bands
are from the same blot. (B) The graph indicates the relative protein expression of
BCL6 and RUVBL1 after normalization for β-actin expression. BCL6 protein ex-
pression (left): mean7SEM for control siRNA 1.78370.556, and for BCL6 siRNA
0.59570.216, p¼0.064. RUVBL1 protein expression (right): mean7SEM for con-
trol siRNA 1.14670.205, and for BCL6 siRNA 2.22970.47, po0.05.
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RUVBL1 produced in rabbit (Sigma-Aldrich Co. LLC, Saint Louis,
MO, #HPA019947), and afﬁnity-isolated actin antibody produced
in rabbit (#A2066, Sigma-Aldrich). Membranes were washed, in-
cubated with anti-rabbit IgG (Fc), alkaline phosphatase conjugate
(Promega, Madison, WI), and washed again. Western Blue Stabi-
lized Substrate for Alkaline Phosphatase (Promega) was used to
detect protein bands. Beta-actin was used to ascertain the amount
of protein loaded, and relative band intensity was normalized to
the intensity of β-actin expression by scanning densitometry. BCL6
and RUVBL1 protein levels in the BCL6 siRNA-transfected cells
were compared with the control nontargeting siRNA-transfected
cells by an unpaired t test.
2.5. ChIP assays
Two ChIP assays were performed with an EZ-ChIP™ Chromatin
Immunoprecipitation Kit (#17-371, EMD Millipore Corp, Billerica,
MA) as described previously [17]. Brieﬂy, BJAB cells, 4.7106 per
sample, were cross-linked with 1% formaldehyde for 5 min at
room temperature. Cross-linked chromatin was sonicated to
∼200–1000 bp with a Microson™ XL 2000 sonicator (Qsonica, LLC,
Newtown, CT), then immunoprecipitated with antibodies to BCL6
(sc-858 X, Santa Cruz Biotechnology, Dallas, TX) and anti-rabbit
IgG as a negative control. ChIP DNA was ampliﬁed by PCR. One
primer set (see Section 2.2) ampliﬁed the BCL6 consensus site in
the promoter of the RUVBL1 gene, and another primer set ampli-
ﬁed a coding region of RUVBL1 which did not contain putative
BCL6 binding sites. These primers ampliﬁed 162 bp within a
199 bp exon that is present in all coding transcripts of RUVBL1
(forward primer, 5′-ACAAACTTCGAGGGGAGATT-3′; reverseprimer, 5′-CGATGGGAGCGATAGAAGAC-3′). Bands were detected
on 0.8% and 1% agarose gels, respectively.
2.6. Immunohistochemistry
Under an Institutional Review Board-approved protocol we
obtained human parafﬁn-embedded tissues from the Surgical Pa-
thology archives. Sections from the same block (not necessarily
consecutive sections) were stained with various antibodies. BCL6
staining was performed as previously described [16–18] with
mouse monoclonal anti-human BCL6 (#M7211, DAKO or clone
LN22, Novocastra). After antigen retrieval for 40 min in a 98° C
waterbath with pH 6 antigen retrieval buffer (DAKO), staining for
RUVBL1 was carried out overnight with an afﬁnity puriﬁed Pres-
tige antibody produced in rabbit (Sigma-Aldrich, St. Louis, MO,
#HPA019947) that was diluted 1:265 to 1:350. Antigen-antibody
binding was detected with DAB chromogen. Tissues were coun-
terstained with hematoxylin. Appropriate positive and negative
controls were used, including a negative isotype-matched control.3. Results
3.1. Subtractive hybridization of BCL6 constructs identiﬁes RUVBL1
as a target of BCL6 repression in BJAB cells
After subtractive hybridization was performed, PCR products of
the experimental subtracted sample showed differentially ex-
pressed bands as compared with the unsubtracted control on a 2%
Fig. 4. ChIP assay. (A) RUVBL1 promoter region containing the high-afﬁnity BCL6
binding site (0.705 kb). In BJAB cells BCL6 is bound (perhaps as part of a complex)
to the region of the RUVBL1 promoter containing the putative BCL6 binding site
(arrow) because DNA from this region is enriched in chromatin im-
munoprecipitated with anti-BCL6 (lane 5). Controls – no antibody (lane 1) and
unrelated antibody, anti-rabbit IgG (lane 2) – do not enrich this genomic region.
The positive (þ) control is genomic DNA ampliﬁed with the same primers (lane 6).
Lane 4 is 1 Kb Plus DNA Ladder (Invitrogen™, Life Technologies, Grand Island, NY);
lane 7 is input. (B) RUVBL1 coding region (0.162 kb, arrow). Binding of BCL6 to a
part of the coding region of RUVBL1 is not observed (lane 2) because there is no
putative binding site. Input (lane 4) and the positive (þ) control, genomic DNA
ampliﬁed with the same primers (lane 5), show the anticipated 162 bp product
(arrow). Lane 3 is 1 Kb Plus DNA Ladder (Invitrogen™).
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identical to overlapping regions of BCL6ZF (indicating identiﬁca-
tion of BCL6ZF mRNA that had been overexpressed in the study
cells) implied that subtractive hybridization was successful. The
sequences from another clone matched the RUVBL1 gene (Gen-
Bank ID NM_003707).
3.2. Differential expression of RUVBL1 conﬁrmed by Northern
blotting
A representative Northern blot hybridized with the cDNA
fragment of RUVBL1 obtained from cDNA subtraction and ampli-
ﬁcation is depicted in Fig. 1A. The expected 1.8-kb transcript [8]
was identiﬁed. Relative band intensity normalized to β-actin by
scanning densitometry showed that differential expression ofRUVBL1 (S lane) as compared with the vector control (C) was, by
unpaired t test, mean7SEM, 2.5970.50 (range, 1.18–5.72)-fold,
po0.006 (Fig. 1B).
3.3. The BCL6 protein represses transcription from the BCL6 con-
sensus site in the RUVBL1 promoter
Transient transfections in 293 T cells showed that relative lu-
ciferase activity was signiﬁcantly repressed (6.8-fold, po0.0001)
from the BCL6 consensus binding site in the promoter of RUVBL1
by the full-length BCL6 protein (mean7SEM¼0.1570.06) as
compared with a truncated construct (control) that cannot bind
DNA (Fig. 2; for comparison, the absolute value of the control was
designated 1). The repression is presumed to be from the BCL6
consensus sequence in the RUVBL1 promoter, but we cannot ex-
clude the possibility that the transfected BCL6 protein might be
driving an intermediary transcription factor acting on another site
in the RUVBL1 promoter.
3.4. Knockdown of the BCL6 protein increases endogenous RUVBL1
expression
Analysis of the Western blots showed that knockdown of BCL6
protein levels and upregulation of RUVBL1 (∼50 kDa) occurred as
early as 18 h after transfection of siRNA duplexes targeting en-
dogenous BCL6; these effects lasted until at least 47 h (Fig. 3A).
Knockdown of the BCL6 protein was 3-fold in the BCL6 siRNA-
transfected cells as compared with controls (po0.06); upregula-
tion of RUVBL1 in the study-transfected cells as compared with
controls was 2-fold (po0.05), Fig. 3B. These data indicate that
upregulation of endogenous RUVBL1 expression is an effect of
BCL6 knockdown.
3.5. BCL6 binding site in the promoter region of the RUVBL1 gene
Tiling ChIP-on-chip studies showed that BCL6 preferentially
localizes to the 8-base consensus binding site [A/T]TC[C/T][A/T][A/
C]GA [13]. We found an exact match to 7 of these bases (TTCTAAG)
in the promoter region of RUVBL1. Two ChIP assays showed that in
BJAB cells endogenous BCL6 was bound, perhaps as part of a
complex [19–21], to the BCL6 consensus site that we identiﬁed in
the promoter region of RUVBL1 because DNA from this region was
enriched in chromatin immunoprecipitated with anti-BCL6
(Fig. 4A, lane 5). Two controls (absence of antibody, Fig. 4A, lane 1)
and an unrelated antibody (anti-rabbit IgG, Fig. 4A, lane 2) did not
enrich DNA from this region. Bands of the correct size were noted
with input (lane 7) and the positive control (genomic DNA, lane 6).
Binding of BCL6 was not detected in a coding region of RUVBL1
which did not contain putative BCL6 binding sites (Fig. 4B, lane 2),
whereas bands in the correct location (Fig. 4B, lanes 4 and 5) were
noted with input and the positive control (genomic DNA).
3.6. Relationship between BCL6 and RUVBL1 expression in Human
lymphomas and benign lymphoid tissue
We studied 22 randomly selected human lymphomas by im-
munohistochemistry (9 T cell and 13 B cell malignancies, termed
“T” or “B”, respectively). If 30% or fewer of the tumor cells stained
with anti-BCL6, lymphomas were considered BCL6 negative [22].
Similarly, if 30% or fewer of the tumor cells stained with anti-
RUVBL1, lymphomas were considered RUVBL1 negative. The data
are summarized in Table 1. Brieﬂy, 13 lymphomas were BCL6 po-
sitive (3 T, 10 B); nine were BCL6 negative (6 T, 3 B). All of the
tumors had some areas that were positive for RUVBL1, and in 20 of
22 lymphomas studied, RUVBL1 expression was greater than that
of BCL6. In two B cell tumors (#13 and #14, Table 1) the reverse
Table 1
BCL6 and RUVBL1 staining in lymphomas.
Tumor Lymphoma type/stage RUVBL1% staining/average intensity BCL6% staining/average intensity % staining average intensity
RUVBL1 BCL6
T cell Localized (stage 1)
1 Anaplastic large cell 80/3þ 50/2þ 240 100
2 Anaplastic large cell 85/3þ 50/2þ 255 100
Advanced (stages 3 and 4)
3 Anaplastic large cell 80/2þ 0 160 0
4 Peripheral 80/2þ 0 160 0
5 Large cell (immunoblastic), peripheral 85/3þ 10/2.5þ 255 25
6 Large cell 80/2þ 25/2þ 160 50
7 Delta/gamma peripheral 90/3þ 25/2þ 270 50
8 Peripheral 67/3þ 30/2þ 201 60
9 Anaplastic large cell 90/3þ 40/2þ 270 80
Avr 219 51.67
B cell Localized (stage 1)
10 High grade, EBV-related 70/2þ/mostly big cells 40/1.5þ/mostly small cells 140 60
11 DLBL, follicular origin 50/2þ 50/1.5þ 100 75
12 Large cell, follicular origin 85/2.5þ 50/3þ 212.5 150
13 DLBL 60/2þ 70/2þ 120 140
14 DLBL, follicular center type 80/1.5þ 80/3þ 120 240
15 DLBL, non-germinal center-like 90/3þ 85/2.5þ 270 212.5
Advanced (stages 3 and 4)
16 Mantle cell 95/3þ 5/2.5þ 285 12.5
17 DLBL 70/1.5þ 25/1.5þ 105 37.5
18 Large cell, follicular origin 60/2.5þ 25/2.5þ 150 62.5
19 DLBL, CD5þ 80/2.5þ 40/2þ 200 80
20 DLBL with anaplastic features 70/3þ 50/2þ 210 100
21 Large cell, activated B cell type 90/3þ 50/2.5þ 270 125
22 DLBL, germinal center-like 90/3þ 60/2.5þ 270 150
Avr 188.65 111.15
DLBL: Diffuse large B cell lymphoma; EBV: Epstein-Barr Virus.
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pression of BCL6 and RUVBL1 that sometimes occurred within the
same lymphoma (e.g., tumor #18 in Table 1 and Fig. 5, panels
2 and 3, in which BCL6 staining was negative in part of the lym-
phoma, where RUVBL1 staining was strong – Fig. 5, panel 2, but
BCL6 positive in another part of the lymphoma, where RUVBL1
staining was negative – panel 3). We called this tumor BCL6 ne-
gative overall, as most of the tissue studied was BCL6 negative.
In Table 1 we have indicated the percent staining times the
average intensity for both RUVBL1 and BCL6. For T cell tumors, a
paired t test comparing this product for RUVBL1 staining with BCL6
staining was statistically signiﬁcant (mean7SEM¼219716.25 for
RUVBL1 and 51.67712.69 for BCL6, po0.0001). This also was true
for B cell tumors (mean7SEM¼188.65719.35 for RUVBL1 and
111.15718.51 for BCL6, p¼0.0097). An unpaired t test showed that
BCL6 staining was signiﬁcantly less in the T cell lymphomas than in
the B cell tumors (mean7SEM¼51.67712.69 in the T cell tumors
and 111.15718.51 in the B cell tumors, po0.03), but there was no
statistically signiﬁcant difference in RUVBL1 staining between T and
B cell tumors. We did not ﬁnd a statistically signiﬁcant increase in
RUVBL1 expression in the advanced (as compared with early stage)
tumors.
Expression of RUVBL1 usually was nuclear, but cytoplasmic
expression also was noted. Intensity of staining is shown in Table 1
and is depicted as an average; it was generally 2þ(moderate) to
3þ(strong) with both the BCL6 and RUVBL1 antibodies, with the
average for RUVBL1 being 2.5þ and for BCL6 2þ . The intensity of
RUVBL1 staining was similar in T and B cell tumors (average 2.7þ
and 2.4þ , respectively), but the intensity of BCL6 expression was
generally less in the T cell tumors than in the B cell tumors
(average 1.6þ vs. 2.2þ , respectively).
Two lymphomas (one B cell, one T cell) occurred within lymph
nodes that contained some residual germinal centers, where, asexpected, BCL6 expression was strong (3þ). RUVBL1 staining
within the germinal centers was nuclear and/or cytoplasmic and
weaker (1þ to 2þ) than in the surrounding tumor tissue.
Sections of six tonsils from patients ranging in age from 3 to 30
years were studied with BCL6 and RUVBL1 antibodies. These tis-
sues were from non-lymphoma patients and showed lymphoid
follicular hyperplasia. As we previously reported [7], BCL6 stains
the nuclei of lymphocytes in germinal centers most heavily in
larger cells (centroblasts). RUVBL1 expression within germinal
centers was strongest where BCL6 expression also was strong and
could be nuclear or cytoplasmic. However, RUVBL1 expression also
was noted in many lymphocytes in the follicular mantle (though
expression in this area was variable), where BCL6 stained only
scattered cells (Fig. 5, panel 4). A negative isotype-matched control
showed no staining.4. Discussion
The RUVBL1 protein, ﬁrst called TIP49, was isolated from rat
liver nuclear extracts by Kanemaki et al. [23]. They identiﬁed it as a
49-kDa protein that was complexed with TATA-binding protein
and had high homology with the RuvB bacterial recombination
factors. The following year Qiu et al. [24] identiﬁed a 50 kDa hu-
man protein in a yeast two-hybrid system (the same protein called
Pontin 52 and TIP49), which they named RUVBL1. Fluorescence
in situ hybridization localized the RUVBL1 gene to 3q21, a region
often rearranged in leukemia and deleted in solid tumors [25].
RUVBL1 was detected in the RNA polymerase II holoenzyme
complex and was essential for yeast viability [24].
Much has been written about RUVBL1. It is a transcriptional
cofactor with ATPase and helicase activities [26], a binding partner
of β-catenin [27], an essential nuclear cofactor for c-MYC
Fig. 5. Immunohistochemistry of representative randomly chosen human lymphomas stained for BCL6 and RUVBL1. The H&E stain shows effacement of normal tissue
architecture by malignant cells. Panel 1: T cell tumor, BCL6 negative, RUVBL1 positive. Panel 2: B cell lymphoma, BCL6 negative area, where RUVBL1 is positive. Panel 3: Same
B cell lymphoma as in panel 2, BCL6 positive area, where RUVBL1 staining is negative. Panel 4: Germinal center of human tonsil; BCL6 and RUVBL1 are both expressed within
the germinal center, but many more lymphocytes outside the germinal center express RUVBL1 as compared with BCL6. The bars in the lower right photos indicate 20 mm for
each image in the corresponding panel.
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during T cell development [29]. Further, it regulates β-catenin-
mediated malignant transformation and T-cell factor target geneinduction via functions on chromatin remodeling [30], and, as a
constituent of chromatin modiﬁcation complexes, may facilitate
the access of repair machinery to DNA-damaged sites [31]. It has
B.W. Baron et al. / Biochemistry and Biophysics Reports 6 (2016) 1–8 7been proposed that interaction of RUVBL1/Reptin with transcrip-
tion-related factors may be important for the initial localization of
these factors to acetylated promoter regions [32]. Working with a
leukemia model, Breig et al. [33] found that RUVBL1 is needed for
cell proliferation rather than cell survival. Others have reported
increased expression of RUVBL1 in advanced (as compared with
early stage) diffuse large B cell lymphomas [34], but BCL6 ex-
pression was not studied. We did not observe this phenomenon in
our study, but the number of tumors that we studied is small.
We previously described other targets of the BCL6 repressive
effects that can induce apoptosis, e.g., the programmed cell death-
2 gene and the integral membrane 2B gene [7,15,17]. Similarly, Jha
et al. suggested that RUVBL1 is required for p53-mediated path-
ways of apoptosis following DNA damage [35]. However, Beresh-
chenko et al. [36] showed that, in the mouse, embryonic stem cells
and hematopoietic tissues contain high expression of RUVBL1,
which is essential for early murine embryogenesis and adult he-
matopoiesis. Conditional ablation of RUVBL1 in hematopoietic
tissues led to bone marrow failure, and studies indicated that this
included the loss of hematopoietic stem cells via apoptosis. They
postulate that inhibition of RUVBL1 expression may inhibit tumor
growth and induce apoptosis in cancer cells. Finally, Taniue et al.
[37] found that RUVBL1 binds to the p53 promoter, repressing its
transcription, and blocks p53-mediated apoptosis in a human co-
lon cancer cell line. As with BCL6, whether apoptosis is induced or
inhibited by RUVBL1 may depend on its cellular context and ex-
pression level [7].
We have presented the following ﬁndings in a B lymphoma cell
line which support the notion that RUVBL1 is a target of BCL6
repression: subtractive hybridization, using a dominant negative
system in which the BCL6 repressive effects were inhibited, fol-
lowed by Northern blotting, indicated differential expression of
RUVBL1; in transient transfection assays the full-length BCL6
protein led to signiﬁcant repression (6.8-fold) from the BCL6
consensus binding site in the promoter of RUVBL1 as compared
with a truncated control that cannot bind DNA (although, as
mentioned, we cannot exclude the possibility that the transfected
BCL6 protein may be driving an intermediary transcription factor);
knockdown of the BCL6 protein by siRNAs increases expression of
the endogenous RUVBL1 protein; and ChIP assays showed that the
BCL6 protein is likely part of a complex that is bound to the pro-
moter region of RUVBL1 in vivo. It has been reported previously
that the BCL6 protein interacts with several corepressors, e.g.,
N-CoR, SMRT, mSIN3A, BCoR, and it is thought that the repressive
effects of BCL6 are mediated through multiprotein repression
complexes [19–21].
We did not observe an inverse relationship between BCL6 and
RUVBL1 within the germinal centers of human tonsils, but ex-
pression of RUVBL1 was more prominent in follicular mantle cells
than BCL6, though the degree of RUVBL1 staining in this area was
variable. In human lymphomas that did not express BCL6, RUVBL1
expression was high, and in some BCL6-negative lymphomas that
showed focal BCL6 expression, we could identify RUVBL1-negative
areas where BCL6 expression was noted. All of the lymphomas
studied expressed RUVBL1, and in both T and B cell tumors
RUVBL1 expression was greater than that of BCL6 in the majority
of the tumors studied (Table 1), although in two B cell tumors the
reverse was true. Studies performed in the BJAB cell line and
transient transfection assays indicate a repressive effect of BCL6 on
its RUVBL1 target. However, in lymphoma tissues, multiple factors
may modulate their respective expression. Others [38] have re-
ported that recruitment of RUVBL1/Reptin complexes is a common
phenomenon in cancer and, at least one mechanism by which this
occurs is via accumulation of the transcription factor E2f1. Thus, it
is possible that the high expression of RUVBL1 we observed in
most of the lymphomas that we studied is a secondaryphenomenon, following its recruitment by this protein or by other
proteins or mechanisms that have not yet been identiﬁed.
The importance of ATPase/helicase motifs has been shown for
several cofactors that function in transcription [28]. Bauer et al.
[27] postulate that the role of RUVBL1 may be to unwind nuclear
duplexes, a step known to be essential for transcription initiation.
As BCL6 is a transcriptional repressor, its relationship with RUVBL1
is likely to be relevant at the transcriptional level, with effects on
additional downstream events that are yet to be ascertained. The
potential risks of prolonged RUVBL1 inhibition (e.g., secondary to
the repressive effects of BCL6), which led to enhanced cancer
progression in a murine model of hepatocellular carcinoma [10]
(see Introduction) may be relevant also to lymphomagenesis. As in
the case of Notch [39], regulation of gene expression by BCL6 is
likely to encompass complex interactions involving co-activators,
cooperating transcription factors, chromatin regulators, and other
factors. How these are coordinated to control the effects of tran-
scription, including the interactions between activator and re-
pressor complexes, is not known. An understanding of the re-
lationship between BCL6 and RUVBL1 during lymphomagenesis
requires further investigation, which may provide insights for the
development of new molecular tools for the targeted treatment of
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